**Author details**

Emine Selin Demir, Emre Ozgenc, Meliha Ekinci, Evren Atlihan Gundogdu\*, Derya İlem Özdemir and Makbule Asikoglu Radiopharmacy Department, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey

\*Address all correspondence to: evren.atlihan@gmail.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**87**

*Computational Study of Radiopharmaceuticals DOI: http://dx.doi.org/10.5772/intechopen.85140*

> Drug Discovery. In: Richard R. Drake, Liam A. McDonnell Editors. Advances in

> [11] Kapetanovic IM. Computer-aided drug discovery and development (CADDD): In silico-chemico-biological

approach. Chemico-Biological Interactions. 2008;**171**(2):165-176

[12] Sahu AK, Jain V. Screening of process variables using Plackett-Burman design in the fabrication of gedunin-loaded liposomes. Artificial Cells Nanomedicine and Biotechnology.

[13] Demir Ö, Aksu B, Özsoy Y. İlaç Formülasyonu Geliştirilmesinde Deney Tasarımı (DoE) Seçimi ve Kullanımı. Marmara Pharmaceutical Journal.

[14] Azuaje F. Computational models for predicting drug responses in cancer research. Briefings in Bioinformatics.

2017;**45**(5):1011-1022

2017;**21**(2):216-227

2017;**18**(5):820-829

[15] Adams JU. Genetics: Big hopes for big data. Nature. 2015;**527**(7578):108-109

the cancer clinic. Nature. 2015;**527**(7576):10-11

2015;**520**(7547):290-291

[16] Schmidt C. Cancer: Reshaping

[18] Kohane IS. Health care policy. Ten things we have to do to achieve precision medicine. Science. 2015;**349**(6243):37-38

[17] Rubin MA. Health: Make precision medicine work for cancer care. Nature.

Cancer Research; 2013:133-171

[10] Michelson S, et al. Target identification and validation using human simulation models. In: León D, Markel S, editors. In Silico Technologies in Drug Target Identification and Validation. Vol. 6. CRC Press/Taylor & Francis Group; 2007;**50**(9):2278-2279

[2] Wadsaka W, Mitterhausera M. Basics and principles of radiopharmaceuticals for PET/CT. European Journal of Radiology. 2010;**73**(3):461-469

Radiopharmaceuticals. Report of a Joint Working Party: The UK Radiopharmacy group and the NHS pharmaceutical quality control committee. Nuclear Medicine Communications.

[5] Aşikoğlu M. In: Gürsoy A, editor. Radyofarmasötikler, Farmasötik Teknoloji Temel Konular Ve Dozaj Şekilleri. Vol. 9. İstanbul: Kontrollü Salım Sistemleri Derneği Yayını; 2004. pp. 399-407

[6] Aşikoğlu M, İlem Özdemir D. Radioimaging and diagnostic

[7] Brian J, Schmidt J, Papin A, Musante CJ. Mechanistic systems modeling to guide drug discovery and development. Drug Discovery Today.

[8] Fernald GH. Bioinformatics challenges for personalized medicine. Bioinformatics. 2011;**27**:1741-1748

[9] Goodwin RJA, Bunch J, McGinnity DF. Mass Spectrometry Imaging in Oncology

2013;**18**(1):116-127

application. In: Senyigit T, Ozcan I, Ozer O, editors. Nanotechnology in Progress. İzmir: IConcept; 2012. pp. 160-173

[3] National Physical Laboratory. Measurement Good Practice Guide No 93. Protocol for Establishing and Maintaining the Calibration of Medical Radionuclide Calibrators and their Quality Control. London: HMSO; 2006

[4] Quality Assurance of

2001;**22**:909-916

[1] Ocak M, Beaino W, White A, Zeng D, Cai Z, Anderson CJ. Cu-64 labeled phosphonate cross-bridged chelator conjugates of c(RGDyK) for PET/CT imaging of osteolytic bone metastases. Cancer Biotherapy and Radiopharmaceuticals. 2018;**33**:74-83

**References**

*Computational Study of Radiopharmaceuticals DOI: http://dx.doi.org/10.5772/intechopen.85140*
